VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Decrease in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 2,472,435 shares, a decline of 34.1% from the September 30th total of 3,750,912 shares. Approximately 5.7% of the company’s shares are sold short. Based on an average daily trading volume, of 1,137,394 shares, the short-interest ratio is presently 2.2 days.

Institutional Trading of VistaGen Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC grew its position in VistaGen Therapeutics by 49.2% in the first quarter. ADAR1 Capital Management LLC now owns 751,141 shares of the company’s stock worth $429,000 after acquiring an additional 247,566 shares in the last quarter. BlackRock Inc. acquired a new position in shares of VistaGen Therapeutics during the 2nd quarter worth $78,000. Renaissance Technologies LLC increased its stake in shares of VistaGen Therapeutics by 81.2% during the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock worth $166,000 after purchasing an additional 130,509 shares during the last quarter. Finally, AdvisorShares Investments LLC increased its stake in shares of VistaGen Therapeutics by 10.8% during the 1st quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock worth $158,000 after purchasing an additional 26,922 shares during the last quarter. 78.39% of the stock is currently owned by institutional investors and hedge funds.

VistaGen Therapeutics Trading Down 0.5%

Shares of NASDAQ:VTGN opened at $0.17 on Tuesday. The firm has a market cap of $7.43 million, a price-to-earnings ratio of -0.10 and a beta of 0.33. VistaGen Therapeutics has a 1 year low of $0.17 and a 1 year high of $5.14. The business has a fifty day simple moving average of $0.24 and a 200 day simple moving average of $0.44.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $0.50 million. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%. On average, sell-side analysts forecast that VistaGen Therapeutics will post -1.45 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, VistaGen Therapeutics currently has a consensus rating of “Reduce” and a consensus target price of $0.95.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines.

Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder.